From the Diabetes Center, Aizawa Hospital, Matsumoto,. Nagano, Japan. Corresponding author: Toru Aizawa, taizawax@ · ai-hosp.or.jp. DOI: 10.2337/dc12- ...
O N L I N E
L E T T E R S
COMMENTS AND RESPONSES Comment on: Harrison et al. b-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy. Diabetes Care 2012;35:1406– 1412
H
arrison et al. (1) analyzed pancreatic b-cell function in drug-naïve patients with type 2 diabetes before and 42 months after treatment with insulin plus metformin or a combination of metformin, glyburide, and pioglitazone. The pretreatment evaluation was not exactly “before” the treatment. It was carried out after 3 months of the run-in period with insulin plus metformin therapy for all participants. The study is well designed, the analysis is appropriate, and the data are straightforward except for two potential drawbacks: absence of a wash-out period prior to the final meal test and failure to pay attention to alteration in insulin sensitivity caused by the treatments. The authors withheld hypoglycemic agents only for 24 h before the final meal test. This is inappropriate to evaluate the disease-modifying effect of the two treatment modalities. Nevertheless,
e16
DIABETES CARE, VOLUME 36, JANUARY 2013
the title says “preservation of b-cell function,” i.e., presence of a disease-modifying effect. Glyburide is especially problematic: the insulinotropic effect of glyburide does not fade away within 24 h (2). Therefore, it is impossible to distinguish a direct insulinotropic effect of the drug and the disease-modifying effect of it with this protocol. It was absolutely needed to stop glyburide at least for a few days, ideally for a week, before the “post-treatment” meal test in order to identify the b-cell preserving effect, if any. Of course, the final meal test should have been carried out after the same wash-out period in the insulin- and metformin-treated group for the fair comparison of the two treatment modalities. The second point is also profoundly important. Pioglitazone’s insulinsensitizing effect may last longer than 24 h (3). In addition, glucose lowering by any means restores insulin sensitivity of the body to some extent (4). Therefore, b-cell function should have been evaluated with alteration of insulin sensitivity taken into consideration, especially after an appropriate wash-out period for pioglitazone. The authors found no change in plasma C-peptide or C-peptide–to– glucose ratio by the two treatments and took the finding as evidence for “preserved b-cell function” (1). However, it may imply improved or worsened b-cell function if insulin sensitivity had gone up or down, respectively. The most popular approach to obviate this problem is calculating oral disposition index (5). At least, the authors should have commented on the above-mentioned two issues as limitations of the study. The title might be misleading in that it gives an impression that the disease-modifying effect, which is of paramount importance, was successfully
achieved by the conventional pharmacological therapies. TORU AIZAWA, MD, PHD KEISHI YAMAUCHI, MD, PHD From the Diabetes Center, Aizawa Hospital, Matsumoto, Nagano, Japan. Corresponding author: Toru Aizawa, taizawax@ ai-hosp.or.jp. DOI: 10.2337/dc12-1419 © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http:// creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Acknowledgments—No potential conflicts of interest relevant to this article were reported. c c c c c c c c c c c c c c c c c c c c c c c c
References 1. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. b-Cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406–1412 2. Bailey CJ, Krentz AJ. Oral antidiabetic agents. In Textbook of Diabetes. 4th ed. Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, Eds. Chichester, Wiley-Blackwell, 2010, p. 452–477 3. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675–691 4. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318– 368 5. Retnakaran R, Qi Y, Goran MI, Hamilton JK. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 2009;26:1198– 1203
care.diabetesjournals.org
